IGF-1 and Growth Response to Adult Height in a Randomized GH Treatment Trial in Short Non-GH-Deficient Children

被引:31
|
作者
Kristrom, Berit [1 ,3 ]
Lundberg, Elena [1 ]
Jonsson, Bjorn [2 ]
Albertsson-Wikland, Kerstin [3 ]
机构
[1] Umea Univ, Dept Clin Sci, SE-90185 Umea, Sweden
[2] Uppsala Univ, Dept Womens & Childrens Hlth, SE-75185 Uppsala, Sweden
[3] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Goteborg Pediat Growth Res Ctr,Dept Pediat, SE-41685 Gothenburg, Sweden
来源
基金
瑞典研究理事会;
关键词
IDIOPATHIC SHORT STATURE; FOR-GESTATIONAL-AGE; LONG-TERM MORTALITY; HORMONE TREATMENT; BINDING PROTEIN-3; FACTOR-I; PREPUBERTAL CHILDREN; FINAL HEIGHT; SECRETION CAPACITIES; PREDICTION MODELS;
D O I
10.1210/jc.2014-1101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: GH treatment significantly increased adult height (AH) in a dose-dependent manner in short non-GH-deficient children in a randomized, controlled, clinical trial; the mean gain in height SD score (height(SDS)) was 1.3 (range 0-3), compared with 0.2 in the untreated group. Objective: The objective of the study was to analyze the relationship between IGF-1(SDS), IGF binding protein-3 SDS (IGFBP3(SDS)), and their ratio(SDS) with a gain in the height(SDS) until AH in non-GH-deficient short children. Design and Setting: This was a randomized, controlled, multicenter clinical trial. Intervention: The intervention included GH treatment: 33 or 67 mu g/kg.d plus untreated controls. Subjects: One hundred fifty-one non-GH-deficient short children were included in the intent-to-treat (ITT) population and 108 in the per-protocol (PP) population; 112 children in the ITT and 68 children in the PP populations had idiopathic short stature (ISS). Main Outcome Measures: Increments from baseline to on-treatment study mean IGF-1(SDS) (Delta IGF-1(SDS)), IGFBP3(SDS), and IGF-1 to IGFBP3 ratio(SDS) were assessed in relationship to the gain in height(SDS). Results: Sixty-two percent of the variance in the gain in height(SDS) in children on GH treatment could be explained by four variables: Delta IGF-1(SDS) (explaining 28%), bone age delay, birth length (the taller the better), and GH dose (the higher the better). The lower IGF-1(SDS) was at baseline, the higher was its increment during treatment. For both the All(PP)- and the ISSPP-treated groups, the attained IGF-1(SDS) study level did not correlate with height gain. Conclusion: In short non-GH-deficient children, the GH dose-related increment in IGF-1(SDS) from baseline to mean study level was the most important explanatory variable for long-term growth response from the peripubertal period until AH, when IGF-1(SDS), IGFBP3(SDS), and their ratio(SDS) were compared concurrently.
引用
收藏
页码:2917 / 2924
页数:8
相关论文
共 50 条
  • [41] The relationship between IGF-1 response and 1st year height velocity on two different doses of GH in idiopathic GH deficiency (IGHD): a randomized, prospective clinical study
    Bundak, Ruveyde
    Arslanoglu, Ilknur
    Berberoglu, Merih
    Siklar, Zeynep
    Isguven, Pinar
    Ocal, Gonul
    Bas, Firdevs
    Ercan, Oya
    Evliyaoglu, Olcay
    Bideci, Aysun
    Darcan, Sukran
    Yuksel, Bilgin
    Cetinkaya, Ergun
    Darendeliler, Feyza
    HORMONE RESEARCH, 2009, 72 : 104 - 105
  • [42] TREATMENT WITH ATENOLOL INCREASES THE GROWTH-HORMONE (GH) RESPONSE TO EXOGENOUS GH RELEASING HORMONE (GHRH) BUT FAILS TO AUGMENT ENDOGENOUS GH SECRETION IN NON-GH DEFICIENT SHORT BOYS
    MARTHA, P
    BLIZZARD, R
    PEZZOLI, S
    THORNER, M
    ROGOL, A
    PEDIATRIC RESEARCH, 1987, 21 (04) : A250 - A250
  • [43] The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults
    Cuneo, RC
    Judd, S
    Wallace, JD
    Perry-Keene, D
    Burger, H
    Lim-Tio, S
    Strauss, B
    Stockigt, J
    Topliss, D
    Alford, F
    Hew, L
    Bode, H
    Conway, A
    Handelsman, D
    Dunn, S
    Boyages, S
    Cheung, NW
    Hurley, D
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (01): : 107 - 116
  • [44] The Effects of Growth Hormone (GH) Treatment on GH and Insulin/IGF-1 Signaling in Long-Lived Ames Dwarf Mice
    Masternak, Michal M.
    Panici, Jacob A.
    Wang, Feiya
    Wang, Zhihui
    Spong, Adam
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2010, 65 (01): : 24 - 30
  • [45] Management of Short Stature: Use of Growth Hormone in GH-Deficient and non-GH–Deficient Conditions
    Varuna Vyas
    Ram K. Menon
    Indian Journal of Pediatrics, 2021, 88 : 1203 - 1208
  • [46] Effect of Growth Hormone (GH) Treatment on The Levels of GHBP in GH Deficient Children (GHD)
    T Salazar
    V Mericq
    M Eggers
    A Avila
    G Iñiguez
    F Cassorla
    Pediatric Research, 1999, 45 : 437 - 437
  • [47] Genomic markers improve the prediction of short-term IGF-I response to growth hormone (GH) in GH-deficient (GHD) children: the PREDICT study
    Chatelain, Pierre
    Tato, Luciano
    Sultanova, Ludmila
    Hou, Jia-Woei
    Coutant, Regis
    Dahlgren, Jovanna
    Theocharis, Theo
    Clayton, Peter
    HORMONE RESEARCH, 2009, 72 : 106 - 106
  • [48] Adult height after growth hormone (GH) treatment for GH deficiency due to cranial irradiation
    Adan, L
    Sainte-Rose, C
    Souberbielle, JC
    Zucker, JM
    Kalifa, C
    Brauner, R
    MEDICAL AND PEDIATRIC ONCOLOGY, 2000, 34 (01): : 14 - 19
  • [49] Effect of growth hormone (GH) treatment on the levels of GHBP in GH deficient children (GHD).
    Salazar, T
    Mericq, V
    Eggers, M
    Avila, A
    Iñiguez, G
    Cassorla, F
    PEDIATRIC RESEARCH, 1999, 45 (03) : 437 - 437
  • [50] Markers of bone turnover in the evaluation of the response to GH treatment in GH-deficient children
    Laursen, T
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 142 (06) : 545 - 547